Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years-Reference-Cited by-同舟云学术

Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years

Published:2016-11-06 Issue:3 Volume:83 Page:593-602
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Bellanti Francesco¹,Del Vecchio Giovanni C.²,Putti Maria C.³,Maggio Aurelio⁴,Filosa Aldo⁵,Cosmi Carlo⁶,Mangiarini Laura⁷,Spino Michael⁸,Connelly John⁸,Ceci Adriana⁷,Della Pasqua Oscar¹⁹,

Affiliation:

1. Leiden Academic Centre for Drug Research; Leiden The Netherlands

2. Paediatric Hematology Unit; Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari; Italy

3. Azienda Ospedaliera di Padova; Italy

4. Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello; Palermo Italy

5. Azienda Ospedaliera Antonio Cardarelli; Naples Italy

6. Clinica Pediatrica Università di Sassari - ASL1; Sassari Italy

7. Consorzio per Valutazioni Biologiche e Farmacologiche; Pavia Italy

8. ApoPharma Inc.; Toronto Ontario Canada

9. Clinical Pharmacology & Therapeutics; University College London; UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13134/fullpdf

Reference35 articles.

1. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands;Southan;Nucl Acids Res,2016

2. Complications of beta-thalassemia major in North America;Cunningham;Blood,2004

3. Survival and complications in thalassemia;Borgna-Pignatti;Ann N Y Acad Sci,2005

4. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major;Borgna-Pignatti;Blood,2006

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose rationale for the use of meropenem/vaborbactam combination in paediatric patients with Gram‐negative bacterial infections;British Journal of Clinical Pharmacology;2024-06-26

2. Iron chelation therapy for children with transfusion‐dependent β‐thalassemia: How young is too young?;Pediatric Blood & Cancer;2024-05-16

3. Clinical Challenges with Iron Chelation in Beta Thalassemia;Hematology/Oncology Clinics of North America;2023-04

4. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia;Cochrane Database of Systematic Reviews;2023-03-06

5. An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes;Expert Review of Hematology;2023-02-01